report season alreadi known ahead earn preview
commerci coverag includ outperform-r
neutral-r anticip larg in-lin quarter
pre-announc think outlook remain strong
see continu launch progress soliri new indic mg nmosd
ultomiri admittedli remain earli day zulresso
remain consensu investor tri better understand path forward
updat estim royalti pharma transact
guidanc target drop final take
opportun introduc estim five compani chang
outperform target look in-lin follow pre-
announc provid partial pre-announc link
model total revenu consensu non-gaap
ep consensu recent kol event continu
hold posit view soliri ultomiri launch commerci
outperform new target upcom readout like import
near term manag pre-releas result target
link much suspens lift upcom report follow
recent top-lin result think investor remain focus
futur readout steroid prophylaxi cohort addit
readout top-lin expans cohort data
outperform target anticip unev report
eye zulresso remain earli launch stage continu
hold revenu estim consensu manag work
process deep dive potenti food effect suggest anoth
potenti factor play recent mountain studi think higher
dose work await manag updat follow fda
neutral new target anticip in-lin updat
eye aducanumab introduc vumer us revenu estim
rais tecfidera us revenu lower us spinraza revenu estim
bring dose assumpt in-lin trend valuat multipl
increas large-cap peer consensu increas
target previous
neutral target continu hold cautiou outlook manag
pre-announc ampyra beat link howev inbrija traction remain elus
manag also lower peak inbrija target rais
ampyra estim lower sg expens estim
target remain unchang continu see challeng path forward
stage
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view sever pre-announc complet mani aspect
report season alreadi known ahead earn preview commerci coverag
includ outperform-r neutral-r
anticip larg in-lin quarter pre-announc think outlook
remain strong see continu launch progress soliri new indic
mg nmosd ultomiri admittedli remain earli day zulresso
remain consensu investor tri better understand path forward
updat estim royalti pharma transact guidanc
target drop final take opportun introduc
estim five compani chang outlook
note bmo market open market close tbd determin ws estim base
overal biotech sector perform trail vertic past month
nbi return versu see figur look close
healthcar subsector note biotech perform lag healthcar technolog
healthcar equip supplier howev trend revers past three
month nbi outperform broader market specif focus three-month
return nbi return versu
note price
note price
herein review company-specif outlook five commercial-stag compani within
coverag univers
outperform target look in-lin report follow pre-
announc report financi result market open
figur depict current estim rel current consensu estim
describ detail herein continu hold posit bia overal stori
result like in-lin versu consensu follow manag recent pre-
announc think on-going ultomiri soliri launch provid continu
momentum
current model total revenu versu consensu non-
ep look beat versu consensu recent kol event
delv fcrn competit landscap continu think ultomiri permit
establish strong foothold across multipl indic market
note product consensu obtain bloomberg total revenu ep estim thomson
make sever adjust estim first rais
soliris/ultomiri franchis estim tie pre-releas revenu growth
figur see addit increas avail us pnh patient treat
carri assumpt forward us market us strensiq revenu also
increas tie manag pre-releas announc metabol
franchis revenu net chang yield total revenu
repres y/i growth consist recent pre-announc
expens side increas estim captur up-front
payment stealth biotherapeut recal achn acquisit yet close tabl
summar chang estim
figur summar financi guidanc provid earn report well
recent pre-announc manag recal pre-announc total revenu
growth excess impli total revenu surpass prior
guid rang manag also report q/q patient volum growth neurolog
franchis mg nmosd target increas franchis patient volum
also pre-announce metabol franchis revenu ahead prior guidanc
final manag pre-announce ultomiri revenu
figur guidanc report pre-announce
note alexion financi guidanc base current foreign exchang rate net hedg activ
includ effect acquisit licens collabor agreement intang asset
impair litig charg chang fair valu conting consider restructur
relat activ outsid previous announc activ may occur issuanc
present reconcili non- financi guidanc provid appendix
avail www alexion com yoy growth use mid-point guidanc rang amount
preliminari estim subject complet audit incom statement fiscal year
stay consist valuat methodolog deriv target via multipl
non-gaap ep estim discount back per year large-cap biotech peer
current trade multipl consensu earn pleas see
detail view valuat incom statement risk clinical/regulatori
outperform target follow mountain anticip unev report
anticip report financi result mid-februari base prior report
period zulresso launch still earli stage manag emphas like
limit traction point compani refin suppli chain get facil
rem certif process work payer/reimburs framework
mind keep zulresso estim consensu unchang think
financi result unlik provid meaning stock move follow recent mountain
data wonder food effect see deep dive note could complic
situat look updat make modif on-going studi
tabl illustr current estim rel consensu valu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
manag plan meet fda discuss potenti modif
develop program think investor also focus current cash runway
compani manag definit indic whether provid cash
runway guidanc upcom earn call instead first wait feedback
agenc develop plan current estim continu assum
financ remov model cash runway project
backdrop lower sg estim carri expens
trajectori forward futur period
chang valuat methodolog continu deriv target via
sum-of-part dcf methodolog examin potenti cash flow zulresso sage-
discount back per year continu hold posit outlook
upcom data point anticip report result mid-februari figur
illustr current estim versu consensu continu hold posit
bia share risk/reward may compel think
recent readout help restor confid potenti gene therapi
platform end continu leav dtx program upsid current
note product consensu obtain bloomberg total revenu ep estim thomson reuter
make sever adjust estim ahead report first
updat forward crysvita revenu estim reflect sale right royalti
pharma see note transact went effect revenu estim
remain unchang current within rang pre-releas figur
layer royalti pharma transact pro forma cash move
consist prior manag guidanc reflect
payment royalti pharma
moder ex-u crysvita revenu trajectori profit
share arrang yield current crysvita revenu estim
respect former ahead manag guidanc
stay consist valuat methodolog use sum-of-part dcf analysi
target drop previous risk clinical/regulatori commerci competit
figur summar recent pre-announc result guidanc target
figur preliminari financi guidanc
note preliminari revenu unaudit subject adjust crysvita revenu guidanc
ultragenyx region exclud non-cash royalti revenu eu preliminari unaudit cash cash
equival available-for-sal invest decemb net cash use oper
plu capit expenditur base current busi exclud potenti genetx option exercis
neutral new target earn matter ye even aducanumab
report financi result market open overal anticip
essenti in-lin report model total revenu consist
consensu also estim non-gaap ep slightli behind
consensu follow recent aducanumab ctad present link note
major investor focu remain center upcom aducanumab file
potenti approv recent host kol call dr martin farlow relat
troriluzol alzheim program link read gener alzheim diseas
space dr farlow opin bar approv may less stringent prior
period given unmet need antibody-focus treatment would without
challeng even less controversi attach data analys trial
tabl compar current estim versu consensu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
make sever adjust estim ahead upcom report first
take opportun introduc vumer estim model recal us
launch underway sever week point although manag
articul regulatori strategi drug ex-u market second increas us
tecfidera estim rais total tecfidera revenu estim
consensu addit increas collabor revenu
estim final lower us spinraza dose assumpt
consist level seen period carri assumpt
forward figur summar chang estim
standard practic manag provid financi guidanc updat
begin year mid-year updat slide provid current
financi guidanc framework updat
note capit expenditur previous anticip rang
large-cap peer trade consensu earn deriv price target
appli multipl previous non-gaap ep estim discount back
per year use framework net model chang yield new target
previous continu hold cautiou outlook aducanumab effort
much risk still product portfolio remain neutral rate share pleas see
detail examin valuat methodolog incom statement risk
neutral target remain cautiou outlook compani pre-
announc result guidanc target limit suspens
upcom earn report expect report financi result
market close figur illustr current estim versu consensu
estim step back ampyra continu gener revenu guidanc
futur tie inbrija recent script trend show sign acceler
uptak keep pressur stori particularli manag recent lower peak
inbrija sale estim bottom line continu see challeng setup
note product consensu obtain bloomberg total revenu ep estim thomson reuter
figur illustr latest inbrija prescrib trend week end
inbrija total rx count declin sinc mid-novemb indic bar
graph averag weekli chang period weekli prescrib count wrx
depict line graph suggest expans size inbrija
prescrib base mean weekli wrx count sinc mid-novemb prescrib
holiday season typic slow prescrib pattern recent data point
week end continu show declin count w/w basi
note acor restructur effort announc late octob unclear
impact may inbrija market effort
make sever adjust estim first updat estim
reflect pre-announc result figur illustr data point releas
manag
figur preliminari financi guidanc
note unaudit oper expens guidanc non-gaap project exclud restructur cost
share-bas compens fulli describ press releas date januari
oblig owe healthcar royalti partner
second rais ampyra end-us revenu estim howev remain
guid rang also trim inbrija revenu ramp base
report revenu manag lower peak revenu assumpt latest script
trend data model inbrija revenu consist guid
rang model non-gaap oper expens high end
manag prior guidanc lower sg expens
better tie guidanc final introduc estim figur shown
illustr differ current estim versu prior estim
net chang yield chang target share trade near
level remain neutral-r stock risk clinical/regulatori commerci
price-to-earnings methodologyearn rate price inc laura chico phd phone email statement good sold gross sg total oper oper profit invest interest incom total non-operating non- pre-tax incom incom tax effect tax rate net incom net net incom basic weight averag common dilut weight average common share dilut weight average common share basic ep dilut ep basic ep dilut ep
price-to-earnings methodologyearn rate price inc laura chico phd phone email statement good sold gross sg amort acquir intang assets- restructur charges- loss divestitur hillerod facility- loss fair valu remeasur conting consideration- collabor profit loss total oper oper profit incom total non-operating non- pre-tax incom incom tax effect tax rate adjust attribut control non- net incom net net incom basic weight averag common dilut weight averag common basic ep dilut ep basic ep dilut ep
sum-of-part npv methodologypric inbrija inbrija ex-u royalty-net acorda therapeut inc laura chico phd phone email statement sales/licens gross sg asset impairment- chang fair valu conting consideration- amort intang acquisition-rel costs- total oper oper profit incom total non-operating non- pre-tax incom incom tax effect tax rate net incom net net incom basic weight averag common dilut weight average common share dilut weight average common share basic ep dilut ep basic ep dilut ep
sum-of-part npv methodologypric -- -- -- pipeline- net inc laura chico phd phone email statement revenue- good sold gross profit- sg total oper oper profit interest incom incom expens total non-operating pre-tax incom incom tax provision- effect tax rate net incom basic weight averag common dilut weight averag common basic ep dilut ep
sum-of-part npv methodologypric pipeline- net inc laura chico phd phone email statement good sold gross sg expense- total oper oper profit gain sale prioriti review voucher- incom expens total non-operating incom loss incom incom tax effect tax rate net incom basic weight averag common dilut weight averag common basic dilut risk attain price rate biotechnolog
risk achiev price target includ advers polit event better worse-than expect clinic data
under-perform outperform rate respect
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
januari
januari
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
